a) Symptomatic classification of EV-A71 patients. (b) EV-A71 sub-genogroup B phylogenetic tree generated by maximum-likelihood analysis of complete VP1 nucleotide sequences aligned using MUSCLE in MEGA. The tree was rooted to the prototype genogroup A strain. Sequences are identified by GenBank accession, country of origin and year of isolation. Viruses in this study are coloured according to their disease severity, and underlined are viruses that were used for characterisation. The robustness of the tree was evaluated by bootstrap analysis using 1000 pseudoreplicate sequences. Bootstrap values >75% of major clades are indicated at relevant branch nodes. All branch lengths are drawn to scale and a measurement of relative phylogenetic distance is provided by the scale at the bottom of the tree.
Supp. Figure S2 Amrun et al. 
SSC-A CD19 SSC-A SSC-A SSC-A

FSC-A FSC-A Live Dead
SSC-A FSC-H SSC-A B cells Monocytes Others CD56lo CD56hi
T cells
Single cells Live cells CD45+
EV-A71-infected
Supplementary Figure S2 . EV-A71 infection in RD cells and primary human PBMCs. (a) RD cells were infected with mild (isolate 1), moderate (isolate 4) and severe (isolate 5) EV-A71 at MOI 10 and harvested at 0, 3, 6, 12 and 24 hpi. Representative dot plots of EV-A71infected RD cells at 12 hpi. (b-c) Quantification of VP1 antigen by flow cytometry of EV-A71 (b) isolates 1, 2 and 3, and (c) isolates 5 and 6 in RD cells at 0, 3, 6, 12 and 24 hpi at MOI 10. Data are presented as mean ± SEM and representative of three independent experiments. Statistical analysis was carried out with Kruskal-Wallis with Dunn's multiple comparisons test to compare among EV-A71 isolates at the respective time-points. (d-e) Human primary PBMCs were infected with mild, moderate, severe and heat-inactivated EV-A71 isolates at MOI 5 and harvested at 0, 6, 12 and 24 hpi. (d) Representative illustration of flow cytometry gating strategy from one donor at 6 hpi. (e) Representative contour plots of EV-A71-infected cell subsets at 12 hpi. Figure S3 . Treatment of PBMCs with LP17 or sLP17 peptide. Human primary PBMCs (n=7) were pre-treated with 100 ng/ml of LP17 or the control sLP17 peptide, before infection with mild, moderate, or severe EV-A71 isolates at MOI 5. Mockinfected and LPS-treated (50 ng/ml) PBMCs were used as negative and positive controls respectively. Cells were replenished with fresh media containing respective peptides and harvested at 24 hpi for gene expression and viral load quantifications. 
